Vienna - Delayed Quote EUR

Carl Zeiss Meditec AG (AFX.VI)

Compare
45.08 -0.82 (-1.79%)
As of 9:05:09 AM GMT+1. Market Open.
Loading Chart for AFX.VI
DELL
  • Previous Close 45.90
  • Open 45.08
  • Bid 43.96 x --
  • Ask 46.58 x --
  • Day's Range 45.08 - 45.08
  • 52 Week Range 45.06 - 123.15
  • Volume 0
  • Avg. Volume 12
  • Market Cap (intraday) 3.946B
  • Beta (5Y Monthly) 1.04
  • PE Ratio (TTM) 22.43
  • EPS (TTM) 2.01
  • Earnings Date Feb 7, 2025 - Feb 11, 2025
  • Forward Dividend & Yield 1.10 (2.02%)
  • Ex-Dividend Date Mar 22, 2024
  • 1y Target Est --

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir

4,823

Full Time Employees

September 30

Fiscal Year Ends

Recent News: AFX.VI

View More

Performance Overview: AFX.VI

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

AFX.VI
1.53%
DAX P
2.01%

1-Year Return

AFX.VI
54.94%
DAX P
21.70%

3-Year Return

AFX.VI
72.95%
DAX P
27.35%

5-Year Return

AFX.VI
60.83%
DAX P
50.50%

Compare To: AFX.VI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AFX.VI

View More

Valuation Measures

Annual
As of 1/9/2025
  • Market Cap

    3.98B

  • Enterprise Value

    4.11B

  • Trailing P/E

    22.84

  • Forward P/E

    18.45

  • PEG Ratio (5yr expected)

    0.88

  • Price/Sales (ttm)

    1.97

  • Price/Book (mrq)

    1.97

  • Enterprise Value/Revenue

    1.99

  • Enterprise Value/EBITDA

    10.20

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.83%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    2.07B

  • Net Income Avi to Common (ttm)

    203.2M

  • Diluted EPS (ttm)

    2.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    15.34M

  • Total Debt/Equity (mrq)

    6.74%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: AFX.VI

View More

Company Insights: AFX.VI

Research Reports: AFX.VI

View More